RA Doesn't Diminish Checkpoint Inhibitors' Survival Benefit

RA Doesn't Diminish Checkpoint Inhibitors' Survival Benefit

(MedPage Today) -- People with rheumatoid arthritis (RA) and comorbid lung cancer showed almost the same overall survival as patients without RA when treated with pembrolizumab (Keytruda) or similar agents, a Medicare claims study indicated. It...

Adjuvant PD-1 blockade for mismatch repair-deficient solid cancers directed by ctDNA status delivers clinical benefit

Pembrolizumab (Keytruda), an anti-PD-1 antibody, cleared minimal residual disease and protected against recurrence in patients with DNA mismatch repair-deficient (dMMR) early-stage solid cancers who had detectable circulating tumor DNA (ctDNA) after resection, according to preliminary results from a phase II trial presented at the American Association for Cancer Research (AACR) Annual Meeting 2025, held April 25–30.

AACR 2025: ctDNA-Guided Adjuvant PD-1 Blockade Shows Promise for Patients With Resected dMMR Solid Tumors

A phase 2 trial showed that using ctDNA to guide adjuvant pembrolizumab therapy after surgery effectively cleared minimal residual disease and reduced recurrence in patients with resected mismatch repair-deficient (dMMR) solid tumors.